Cantor Fitzgerald set a $112.00 price target on Celgene (NASDAQ:CELG) in a research report released on Wednesday, January 17th. The brokerage currently has a hold rating on the biopharmaceutical company’s stock.
“The Wall Street Journal (WSJ) has reported that CELG is in talks to buy JUNO (NC), or rather the 90% of the company that CELG does not already own.”,” the firm’s analyst wrote.
Several other equities analysts also recently commented on CELG. Piper Jaffray Companies reissued a neutral rating and issued a $133.00 target price on shares of Celgene in a report on Monday, October 23rd. Stifel Nicolaus reduced their price target on shares of Celgene from $155.00 to $149.00 and set a buy rating on the stock in a research report on Friday, October 20th. Leerink Swann reiterated a buy rating and set a $120.00 price objective on shares of Celgene in a research report on Friday, December 22nd. Credit Suisse Group set a $125.00 price objective on shares of Celgene and gave the company a buy rating in a research report on Monday, January 8th. Finally, SunTrust Banks set a $127.00 price objective on shares of Celgene and gave the company a buy rating in a research report on Monday, January 8th. Two research analysts have rated the stock with a sell rating, thirteen have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $130.35.
Shares of Celgene (NASDAQ CELG) traded up $1.49 during trading hours on Wednesday, reaching $92.51. 10,465,217 shares of the company’s stock traded hands, compared to its average volume of 8,240,000. The company has a debt-to-equity ratio of 2.29, a current ratio of 4.99 and a quick ratio of 3.52. Celgene has a twelve month low of $88.32 and a twelve month high of $147.17. The stock has a market capitalization of $69,580.00, a P/E ratio of 25.63, a P/E/G ratio of 0.66 and a beta of 1.49.
Celgene (NASDAQ:CELG) last issued its quarterly earnings results on Thursday, January 25th. The biopharmaceutical company reported $1.87 earnings per share for the quarter, beating the consensus estimate of $1.78 by $0.09. Celgene had a net margin of 22.38% and a return on equity of 67.50%. The business had revenue of $3.48 billion for the quarter, compared to the consensus estimate of $3.46 billion. During the same quarter in the previous year, the firm earned $1.61 earnings per share. The company’s revenue for the quarter was up 16.9% on a year-over-year basis. research analysts expect that Celgene will post 7.68 EPS for the current year.
In other Celgene news, insider Mark J. Alles purchased 3,260 shares of the business’s stock in a transaction that occurred on Thursday, February 8th. The shares were bought at an average price of $91.90 per share, for a total transaction of $299,594.00. Following the acquisition, the insider now owns 178,904 shares in the company, valued at $16,441,277.60. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 0.95% of the stock is currently owned by corporate insiders.
Several hedge funds and other institutional investors have recently modified their holdings of CELG. Janus Henderson Group PLC grew its stake in shares of Celgene by 4,290.5% during the 2nd quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock worth $1,092,071,000 after purchasing an additional 8,217,433 shares during the period. BlackRock Inc. lifted its position in shares of Celgene by 5.7% during the 2nd quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. purchased a new position in shares of Celgene during the 2nd quarter valued at approximately $271,605,000. Arrowstreet Capital Limited Partnership lifted its position in shares of Celgene by 1,489.2% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,907,052 shares of the biopharmaceutical company’s stock valued at $247,669,000 after buying an additional 1,787,052 shares in the last quarter. Finally, Vanguard Group Inc. lifted its position in shares of Celgene by 3.1% during the 2nd quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares in the last quarter. 78.93% of the stock is currently owned by institutional investors and hedge funds.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Receive News & Ratings for Celgene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene and related companies with MarketBeat.com's FREE daily email newsletter.